Literature DB >> 18602124

N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein.

Zhenyu Sheng1, Mary Prorok, Brigid E Brown, Francis J Castellino.   

Abstract

The effects of a synthetic apoE peptide, viz., residues 133-149 (apoE[133-149]), a mimetic that comprises the apoE receptor binding domain, on N-methyl-D-aspartate (NMDA)/glycine-induced ion flow through NMDA receptor (NMDAR) channels, have been investigated. The activity of apoE[133-149] was found to depend on the low-density lipoprotein receptor-related protein (LRP). Competition experiments with receptor-associated protein (RAP) and activated alpha(2)-macroglobulin (alpha(2)M*), two proteins that compete for apoE binding to LRP, demonstrate that apoE[133-149] inhibition of NMDAR function is mediated at a locus in LRP that overlaps with the binding sites of RAP and alpha(2)M*. A coreceptor of LRP, cell surface heparin sulfate proteoglycan, did not function in this system. Additional electrophysiology experiments demonstrated that the inhibitory potency of apoE[133-149] was threefold greater for NMDAR-transfected wild-type Chinese hamster ovary (CHO) cells compared with NMDAR-transfected CHO cells deficient in LRP. Studies with truncation and replacement variants of the apoE peptide demonstrated that the NMDAR inhibitory properties of these peptides correlate with their binding affinities for LRP. These novel results indicate that apoE functions as an inhibitor of NMDAR ion channels indirectly via LRP, and are suggestive of a participatory role for LRP in NMDAR-based neuropathies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602124      PMCID: PMC2610414          DOI: 10.1016/j.neuropharm.2008.05.016

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  61 in total

1.  Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains.

Authors:  L P Aggerbeck; J R Wetterau; K H Weisgraber; C S Wu; F T Lindgren
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

2.  Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains.

Authors:  J R Wetterau; L P Aggerbeck; S C Rall; K H Weisgraber
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

3.  Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E.

Authors:  C Wilson; M R Wardell; K H Weisgraber; R W Mahley; D A Agard
Journal:  Science       Date:  1991-06-28       Impact factor: 47.728

4.  Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor.

Authors:  D K Strickland; J D Ashcom; S Williams; W H Burgess; M Migliorini; W S Argraves
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

5.  Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.

Authors:  K H Weisgraber
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

6.  Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3.

Authors:  K H Weisgraber; S C Rall; R W Mahley; R W Milne; Y L Marcel; J T Sparrow
Journal:  J Biol Chem       Date:  1986-02-15       Impact factor: 5.157

7.  Cortical plasticity in Alzheimer's disease in humans and rodents.

Authors:  Fortunato Battaglia; Hoau-Yan Wang; M Felice Ghilardi; Eleonora Gashi; Angelo Quartarone; Eitan Friedman; Ralph A Nixon
Journal:  Biol Psychiatry       Date:  2007-07-25       Impact factor: 13.382

8.  Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions.

Authors:  A Lalazar; K H Weisgraber; S C Rall; H Giladi; T L Innerarity; A Z Levanon; J K Boyles; B Amit; M Gorecki; R W Mahley
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

9.  The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.

Authors:  T L Innerarity; E J Friedlander; S C Rall; K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

10.  Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia.

Authors:  J Dallongeville; M Roy; N Leboeuf; M Xhignesse; J Davignon; S Lussier-Cacan
Journal:  Arterioscler Thromb       Date:  1991 Mar-Apr
View more
  17 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

3.  The NMDA receptor functions independently and as an LRP1 co-receptor to promote Schwann cell survival and migration.

Authors:  Elisabetta Mantuano; Michael S Lam; Masataka Shibayama; W Marie Campana; Steven L Gonias
Journal:  J Cell Sci       Date:  2015-08-13       Impact factor: 5.285

4.  LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein.

Authors:  Elisabetta Mantuano; Michael S Lam; Steven L Gonias
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

Review 5.  Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury.

Authors:  Michael L James; Jordan M Komisarow; Haichen Wang; Daniel T Laskowitz
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

6.  An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury.

Authors:  Feng-Qiao Li; Kenneth A Fowler; Jessica E Neil; Carol A Colton; Michael P Vitek
Journal:  J Pharmacol Exp Ther       Date:  2010-04-20       Impact factor: 4.030

7.  Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects.

Authors:  Jeffrey T Guptill; Shruti M Raja; Felix Boakye-Agyeman; Robert Noveck; Sarah Ramey; Tian Ming Tu; Daniel T Laskowitz
Journal:  J Clin Pharmacol       Date:  2016-12-19       Impact factor: 3.126

8.  Full-length apolipoprotein E protects against the neurotoxicity of an apoE-related peptide.

Authors:  K A Crutcher; H N Lilley; S R Anthony; W Zhou; V Narayanaswami
Journal:  Brain Res       Date:  2009-10-21       Impact factor: 3.252

9.  Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease.

Authors:  Svetlana Sarantseva; Svetlana Timoshenko; Olga Bolshakova; Eugenia Karaseva; Dmitry Rodin; Alexander L Schwarzman; Michael P Vitek
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

10.  A soluble derivative of PrPC activates cell-signaling and regulates cell physiology through LRP1 and the NMDA receptor.

Authors:  Elisabetta Mantuano; Pardis Azmoon; Michael A Banki; Michael S Lam; Christina J Sigurdson; Steven L Gonias
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.